Loading
regulation
No description yet: the sentence for this tag has not been written. 15 records carry it: 14 people, 1 technology.
Related tags
By kind
15 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Anthony Lawler Head of the Therapeutic Goods Administration and Deputy Secretary, Health Products Regulation Group (since 2023) · Therapeutic Goods Administration Head of Australia's medicines and medical devices regulator, the body that approves cancer drugs for the Australian market. | none | none | leadership, australia | ||
Chris Decker President and Chief Executive Officer · Clinical Data Interchange Standards Consortium Leads CDISC, the non-profit that sets the clinical trial data standards required by FDA and PMDA, including oncology-specific therapeutic area guides. | none | none | leadership, data standards | ||
Emer Cooke Executive Director · European Medicines Agency Executive Director of the European Medicines Agency since November 2020, overseeing EU approval of cancer medicines. | none | none | leadership, drug approval | ||
Gilles Vassal Board member, Oncopolicy · SIOP Europe (European Society for Paediatric Oncology) Gustave Roussy paediatric oncologist and past SIOPE president who leads its oncopolicy work and helped shape European paediatric medicines regulation. | none | none | leadership, clinician-scientist, paediatric oncology | ||
Huang Guo Commissioner, National Medical Products Administration (NMPA), China · National Medical Products Administration / Center for Drug Evaluation Commissioner of China's National Medical Products Administration, the regulator whose Center for Drug Evaluation reviews new cancer drugs for the Chinese market. | none | none | leadership, government | ||
Jean Lessi Director General · Haute Autorité de Santé Director General of the Haute Autorité de Santé, responsible for the agency's operations since January 2024. | none | none | leadership, health technology assessment | ||
Joseph S. Ross Professor of Medicine (General Medicine) and of Public Health (Health Policy) · Yale University Open Data Access (YODA) Project Yale health policy researcher on the YODA Project leadership team, known for work on FDA regulation and trial transparency. | none | none | clinician-scientist, data sharing | ||
Lawrence Tallon Chief Executive · Medicines and Healthcare products Regulatory Agency Chief Executive of the UK Medicines and Healthcare products Regulatory Agency, the body that approves and monitors cancer medicines and devices in the UK. | none | none | leadership | ||
Lionel Collet President of the Collège · Haute Autorité de Santé Physician and former university president who chairs the Haute Autorité de Santé, France's health technology assessment and quality body. | none | none | leadership, health technology assessment | ||
Long-term follow-up for gene-modified cell products: fifteen years, and why If you were given a treatment in which your own cells were genetically modified, you are expected to be followed up for fifteen years. Not because something is known to go wrong, but because the gene is inserted permanently and the only honest way to find out what happens over a lifetime is to look. | none | rejuvenation, survivorship, transplant | |||
Rajeev Singh Raghuvanshi Drugs Controller General of India, Central Drugs Standard Control Organisation (CDSCO) · Central Drugs Standard Control Organization India's Drugs Controller General, who heads the Central Drugs Standard Control Organisation, the national regulator for medicines, medical devices and clinical trials. | none | none | leadership, government | ||
Shalene Curtis-Micallef Deputy Minister of Health · Health Canada Senior public servant who has led Health Canada as Deputy Minister since January 2026, after serving as Canada's Deputy Minister of Justice. | none | none | leadership, government | ||
Sonja Optendrenk Impartial Chair (Unparteiische Vorsitzende), Gemeinsamer Bundesausschuss · Gemeinsamer Bundesausschuss / IQWiG Impartial chair of Germany's Federal Joint Committee (G-BA), the body that decides which treatments statutory health insurance covers. | none | none | leadership, health technology assessment | ||
Thomas Kaiser Director (Institutsleiter), IQWiG · Gemeinsamer Bundesausschuss / IQWiG Physician who directs IQWiG, the German institute that produces the benefit assessments underpinning cancer drug pricing and coverage decisions. | none | none | leadership, health technology assessment | ||
Yasuhiro Fujiwara Chief Executive · Pharmaceuticals and Medical Devices Agency Medical oncologist who heads Japan's Pharmaceuticals and Medical Devices Agency, the national drug and device regulator. | none | none | leadership, drug development |
